From the administrative staff to your attending physician, we want your relationship with Duke to be as professional, courteous and successful as possible. Our clinical research office combines cutting edge research with compassionate care. As a leading research institution, Duke Radiation Oncology fields numerous clinical trials across all cancer sites.
The research trials conducted by our faculty include radiation therapy, radiation therapy combined with chemotherapy agents, devices, imaging studies, supportive care, quality of life and tissue/blood sampling research. Clinical trials are vital in the development and approval of new therapies. Ask your doctor about clinical trial options in radiation oncology that could be available for you.
Current Clinical Trials
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
e110602 Biorepository for Circulating Biomarkers in Brain Tumors
Duke Principal Investigators: Dr. Scott Floyd and Dr. Zach Reitman
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT)
e116773 TAILOR-RT for Low Risk Breast Cancer
Duke Principal Investigator: Dr. Susan McDuff
Evaluation of Ascorbate-Meglumine Therapeutic for SRS
e114101 LadeRX (Ascorbate-Meglumine and SRS)
Duke Principal Investigator: Dr. John Kirkpatrick
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx
e105899 H/N PET Dose De-escalation
Duke Principal Investigator: Dr. David Brizel
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
e89525 PROVE-HCC
Duke Principal Investigator: Dr. Manisha Palta
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
e108295 NRG-GU009
Duke Principal Investigators: Drs. Matthew Boyer and Ryan Fecteau
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
e113621 NRG-GU010
Duke Principal Investigator: Dr. Matthew Boyer
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
e117320 NRG-GU012 Renal Cell Carcinoma
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III (GROINSS-VIII)
e109439 NRG-GY024 Vulvar Cancer
Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking (TRUS)
e113768 TRUS
Duke Principal Investigator: Dr. Diandra Ayala-Peacock
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
e116500 NRG-LU008 for locally advanced non-small cell lung cancer
Duke Principal Investigator: Dr. Christopher Kelsey
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
e103137 Oligomets – Registry Study
Duke Principal Investigator: Dr. Joseph Salama
Eye Plaque Brachytherapy for Ocular Melanoma (PROMPT)
e115893 PROMPT Ocular Melanoma Radiation Therapy Registry
Duke Principal Investigator: Dr. Dianda Ayala-Peacock